Comparison of the efficacy and safety of one inhalation of Symbicort Turbuhaler 160/4.5 mcg bid plus as-needed with two inhalations of SeretideTM EvohalerTM 25/125 mcg bid plus Terbutaline Turbuhaler 0.4 mg as-needed, and one inhalation of Symbicort Turbuhaler 320/9 mcg bid plus Terbutaline Turbuhaler 0.4 mg as-needed. A 6-month, randomised, double-blind, double-dummy, parallel-group, active-controlled, multicentre, phase IIIB study in adult and adolescent asthmatic patients.

尚未翻譯 尚未翻譯
作者
类别 Primary study
Registry of TrialsAstraZeneca Clinical Trials ID SD-039-0735
Year 1971
此文章尚無摘要
Epistemonikos ID: 3a5dee26780a98ccd7251c4f41e308989e0d9367
First added on: Jan 10, 2014